The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
151
Central Research Associates - Flourish - PPDS
Birmingham, Alabama, United States
Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS
Anaheim, California, United States
Percentage Change in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis
Time frame: Baseline (Week 9) to Week 20
Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Lean Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Total Body Fat Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Percentage Visceral Fat Mass as Measured by DXA
Time frame: Baseline (Week 9) to Week 20
Change in Glycemic Parameters from Baseline (Week 9) to Week 20
Change in HbA1c and fasting plasma glucose levels from baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Lipid Parameters from Baseline (Week 9) to Week 20
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
Los Alamitos, California, United States
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida, United States
ForCare Clinical Research - CenExel FCR - PPDS
Tampa, Florida, United States
Atlanta Center for Medical Research - CenExel ACMR - PPDS
Atlanta, Georgia, United States
iResearch Atlanta - CenExel - PPDS
Decatur, Georgia, United States
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis
Richfield, Minnesota, United States
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS
Omaha, Nebraska, United States
Velocity Clinical Research - Durham - PPDS
Durham, North Carolina, United States
...and 5 more locations
Time frame: Baseline (Week 9) to Week 20
Change in Body Weight (kg) from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Proportion of Participants Achieving ≥2% and ≥3% Reduction in Body Weight from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Alanine Aminotransferase (ALT) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Aspartate Aminotransferase (AST) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Alkaline Phosphatase (ALP) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Change in Gamma-Glutamyl Transferase (GGT) Levels from Baseline (Week 9) to Week 20
Time frame: Baseline (Week 9) to Week 20
Frequency of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose through Week 20 (or end of study visit)
Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose through Week 20 (or end of study visit)
Laboratory Safety Evaluations
changes in clinical laboratory parameters, including hematology, serum chemistry, and urinalysis.
Time frame: Baseline through Week 20
Changes in 12-Lead Electrocardiogram (ECG) Parameters
Change in QT Interval, etc
Time frame: Baseline through Week 20
Changes in Vital Signs Findings
including blood pressure, etc
Time frame: Baseline through Week 20
Changes in Physical Examination Findings
including blood pressure, etc
Time frame: Baseline through Week 20